RecruitingNot applicableNCT05577819

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

Studying Amyloidosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Massachusetts General Hospital
Principal Investigator
Hanna K Gaggin, MD
Massachusetts General Hospital
Intervention
99mTc-pyrophosphate Scintigraphy(diagnostic_test)
Enrollment
515 enrolled
Eligibility
65 years · All sexes
Timeline
20202026

Study locations (1)

Collaborators

Akcea Therapeutics · Pfizer · Alnylam Pharmaceuticals · Eidos Therapeutics, a BridgeBio company

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05577819 on ClinicalTrials.gov

Other trials for Amyloidosis

Additional recruiting or active studies for the same condition.

See all trials for Amyloidosis

← Back to all trials